BLOG

Honoring Dwight Clark’s Legacy: A Conversation with Steve Young

Published September 2, 2025

At Spinogenix, stories of courage and perseverance drive our mission in developing the novel synaptic regenerative treatments to bring new hope to people living with ALS and other neurodegenerative diseases.

In a recent conversation with our founder and CEO, Dr. Stella Sarraf, Hall of Fame quarterback, philanthropist, and Spinogenix board member Steve Young reflected on how his friend and teammate Dwight Clark’s battle with ALS continues to fuel this mission.

Dwight’s legacy—defined by strength, perseverance, and hope—reminds us why advancing restorative treatments matters so deeply. As Steve shares, Spinogenix is working to pave the way for a new era of therapies that honor that legacy and bring new possibilities to people affected by ALS and their families.

Watch the full conversation below.

Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory

Insights from the failed Harmony Zygel Trial and hope on the horizon with Spinogenix’sSPG601

Restoring Synapses, Restoring Hope: A Conversation with Jerre Stead

Honoring Dwight Clark’s Legacy: A Conversation with Steve Young

Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD

Restoring Synapses to Fight Neurodegeneration with Spinogenix CEO Dr. Stella Sarraf — Episode 217

Spinogenix CEO and Founder Named to Forbes 50 Over 50: Innovation List

This Founder Wants To Help Alzheimer’s Patients Restore Memory. Plus: Stop Spinning Your Wheels

A New Era in Schizophrenia Treatment: Dr. Christoph U. Correll on the Promise of SPG302

Spinogenix Reports Positive Phase 2 Results for SPG601 in Fragile X Syndrome

Addressing the unmet need for synaptic regeneration in Schizophrenia

Addressing Synaptic Deficits in Fragile X syndrome and how SPG601 could help

Synapse loss in Alzheimer’s disease and how SPG302 can help

Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach

Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials